Related references
Note: Only part of the references are listed.Sex-Specific Association between Antioxidant Defense System and Therapeutic Response to Risperidone in Schizophrenia: A Prospective Longitudinal Study
Haixia Liu et al.
CURRENT NEUROPHARMACOLOGY (2022)
Changes in Histaminergic System in Neuropsychiatric Disorders and the Potential Treatment Consequences
Ling Shan et al.
CURRENT NEUROPHARMACOLOGY (2022)
Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study
Haixia Liu et al.
CURRENT NEUROPHARMACOLOGY (2022)
Sex differences in metabolic disorder patterns of first-episode drug-naive patients with schizophrenia
Yongjie Zhou et al.
PSYCHONEUROENDOCRINOLOGY (2021)
Sex difference in the interrelationship between TNF-α and oxidative stress status in first-episode drug-naive schizophrenia
Minghuan Zhu et al.
JOURNAL OF NEUROINFLAMMATION (2021)
A follow-up study of metabolic syndrome in schizophrenia
Gokhan Yoca et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2020)
Drug-induced hyperglycaemia and diabetes: pharmacogenomics perspectives
Mou-Ze Liu et al.
ARCHIVES OF PHARMACAL RESEARCH (2018)
Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia
Yezhe Lin et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2018)
The Influence of Metabolic Syndrome and Sex on the DNA Methylome in Schizophrenia
Kyle J. Burghardt et al.
INTERNATIONAL JOURNAL OF GENOMICS (2018)
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
Sharea Ijaz et al.
BMC PSYCHIATRY (2018)
Increased plasma leptin as a novel predictor for psychopathological depressive symptoms in chronic schizophrenia
Jinjie Xu et al.
GENERAL PSYCHIATRY (2018)
Complement 3 and metabolic syndrome induced by clozapine: a cross-sectional study and retrospective cohort analysis
C. Zhang et al.
PHARMACOGENOMICS JOURNAL (2017)
Physical Activity Levels and Psychosis: A Mediation Analysis of Factors Influencing Physical Activity Target Achievement Among 204 186 People Across 46 Low- and Middle-Income Countries
Brendon Stubbs et al.
SCHIZOPHRENIA BULLETIN (2017)
Prevalence of Metabolic Syndrome in Patients with Schizophrenia in Korea: A Multicenter Nationwide Cross-Sectional Study
Jung Sun Lee et al.
PSYCHIATRY INVESTIGATION (2017)
Cardiovascular consequences of metabolic syndrome
Johnathan D. Tune et al.
TRANSLATIONAL RESEARCH (2017)
Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls
Christoph U. Correll et al.
WORLD PSYCHIATRY (2017)
Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies
Lauren Hirsch et al.
DRUG SAFETY (2017)
Metabolic syndrome and cardiovascular risk among institutionalized patients with schizophrenia receiving long term tertiary care
Lee Seng Esmond Seow et al.
COMPREHENSIVE PSYCHIATRY (2017)
A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia
Stefanie Malan-Mueller et al.
SCHIZOPHRENIA RESEARCH (2016)
Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology
Leonel E. Rojo et al.
PHARMACOLOGICAL RESEARCH (2015)
Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
MARC DE HERT et al.
World Psychiatry (2015)
Excess Early Mortality in Schizophrenia
Thomas Munk Laursen et al.
ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 10 (2014)
Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999-2010
Hiram Beltran-Sanchez et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Clozapine-Induced Mitochondria Alterations and Inflammation in Brain and Insulin-Responsive Cells
Veronica Contreras-Shannon et al.
PLOS ONE (2013)
Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders-A Systematic Review and Meta-Analysis
Alex J. Mitchell et al.
SCHIZOPHRENIA BULLETIN (2013)
Premature death among people with mental illness
Graham Thornicroft
BMJ-BRITISH MEDICAL JOURNAL (2013)
The prevalence and clinical correlates of metabolic syndrome in patients with schizophrenia: findings from a cohort in Turkey
M. K. Yazici et al.
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2011)
Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia
Norio Sugawara et al.
ANNALS OF GENERAL PSYCHIATRY (2011)
The Metabolic Syndrome and Cardiovascular Risk A Systematic Review and Meta-Analysis
Salvatore Mottillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan
M. -C. Huang et al.
ACTA PSYCHIATRICA SCANDINAVICA (2009)
Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
Lizheng Shi et al.
BMC PSYCHIATRY (2009)
PREVALENCE OF METABOLIC SYNDROME AMONG AN IRANIAN COHORT OF INPATIENTS WITH SCHIZOPHRENIA
Omid Rezaei et al.
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE (2009)
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Marc De Hert et al.
SCHIZOPHRENIA RESEARCH (2008)
Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variants
Vicki L. Ellingrod et al.
SCHIZOPHRENIA RESEARCH (2008)
Metabolic syndrome in first episode schizophrenia - A randomized double-blind controlled, short-term prospective study
Sahoo Saddichha et al.
SCHIZOPHRENIA RESEARCH (2008)
Pharmacology of N-desmethylclozapine
Jelveh Lameh et al.
PHARMACOLOGY & THERAPEUTICS (2007)
Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey
Jaana M. Suvisaari et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
The elucidation of the mechanism of weight gain and glucose tolerance abnormalities induced by chlorpromazine
Takahiro Amamoto et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2006)
Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring
M De Hert et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2006)
Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
MA De Hert et al.
SCHIZOPHRENIA RESEARCH (2006)
Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease
Derrick Heng et al.
ATHEROSCLEROSIS (2006)
Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice:: Implications for obsessive-compulsive disorder
M Matsushita et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2005)
Metabolic syndrome and 10-year cardiovascular disease risk in the hoorn study
JM Dekker et al.
CIRCULATION (2005)
The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment
GP Reynolds et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2005)
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
C Barba et al.
LANCET (2004)
The Finnish Diabetes Prevention Study (DPS)
J Lindstrom et al.
DIABETES CARE (2003)
Factor analysis of metabolic syndrome using directly measured insulin sensitivity - The Insulin Resistance Atherosclerosis Study
AJG Hanley et al.
DIABETES (2002)
Factor analysis of the metabolic syndrome:: obesity vs insulin resistance as the central abnormality
PJ Anderson et al.
INTERNATIONAL JOURNAL OF OBESITY (2001)
Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy
A Inoue et al.
JAPANESE JOURNAL OF PHARMACOLOGY (2001)
Share Paper
